BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22921927)

  • 1. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Matheus FC; Aguiar AS; Castro AA; Villarinho JG; Ferreira J; Figueiredo CP; Walz R; Santos AR; Tasca CI; Prediger RD
    Behav Brain Res; 2012 Dec; 235(2):263-72. PubMed ID: 22921927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
    Castro AA; Ghisoni K; Latini A; Quevedo J; Tasca CI; Prediger RD
    Behav Brain Res; 2012 Apr; 229(1):208-15. PubMed ID: 22266923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
    Castro AA; Wiemes BP; Matheus FC; Lapa FR; Viola GG; Santos AR; Tasca CI; Prediger RD
    Brain Res; 2013 Jun; 1513():103-16. PubMed ID: 23548600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.
    Anandhan A; Tamilselvam K; Radhiga T; Rao S; Essa MM; Manivasagam T
    Brain Res; 2012 Jan; 1433():104-13. PubMed ID: 22138428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
    Liu LX; Chen WF; Xie JX; Wong MS
    Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
    Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
    Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
    Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
    Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
    Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
    FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease.
    Monaghan MM; Leddy L; Sung ML; Albinson K; Kubek K; Pangalos MN; Reinhart PH; Zaleska MM; Comery TA
    Neurodegener Dis; 2010; 7(1-3):153-9. PubMed ID: 20197696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
    Schmidt N; Ferger B
    Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
    Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
    Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.
    Reksidler AB; Lima MM; Dombrowski P; Andersen ML; Zanata SM; Andreatini R; Tufik S; Vital MA
    J Neurosci Methods; 2008 Jan; 167(2):268-77. PubMed ID: 17931705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.
    Hsieh MH; Gu SL; Ho SC; Pawlak CR; Lin CL; Ho YJ; Lai TJ; Wu FY
    Behav Brain Res; 2012 Apr; 229(1):41-7. PubMed ID: 22227506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
    van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
    Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
    Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
    J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.